Heron Therapeutics (HRTX) Current Deferred Revenue (2010 - 2018)

Heron Therapeutics has reported Current Deferred Revenue for 4 years, with the latest figure at $14.0 million in Q4 2018.

• For the quarter ending Q4 2018, Current Deferred Revenue rose 407.06% year-over-year to $14.0 million; the trailing twelve-month figure through Dec 2018 stood at $14.0 million (up 407.06% YoY), and the FY2018 full-year result was $14.0 million, up 407.06% from the prior year.
• Current Deferred Revenue for Q4 2018 stood at $14.0 million, up from $10.5 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $14.0 million in Q4 2018, with the low at $1.1 million in Q4 2016.
• Historically, Current Deferred Revenue has averaged $6.2 million across 3 years, with a median of $5.2 million in 2017.
• The largest YoY upside for Current Deferred Revenue was 407.06% in 2018 against a maximum downside of 55.21% in 2018.
• Heron Therapeutics' Current Deferred Revenue stood at $1.1 million in 2016, then soared by 151.41% to $2.8 million in 2017, then surged by 407.06% to $14.0 million in 2018.
• The last three Current Deferred Revenue figures came in at $14.0 million (Q4 2018), $10.5 million (Q3 2018), and $9.4 million (Q2 2018), per Business Quant data.